Eftilagimod alfa is under clinical development by Immutep and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData, Phase II drugs for Soft Tissue Sarcoma have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Eftilagimod alfa’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Eftilagimod alfa overview
Eftilagimod alfa (IMP-321, EDP-202) is under development for the treatment of HER2-negative hormone receptor-positive metastatic breast cancer, soft tissue sarcoma including undifferentiated pleomorphic sarcoma (UPS), myxofibrosarcoma, dedifferentiated liposarcoma (DDLPS), myxoid and round cell liposarcoma (MRCLPS), epithelioid sarcoma (ES), angiosarcoma (AS), peritoneal cancer, non-squamous non-small cell lung cancer (NSCLC), recurrent head and neck cancer squamous cell carcinoma, as an adjuvant therapy for metastatic melanoma, hepatocellular carcinoma, metastatic urothelial cancer and solid tumors. It is administered through subcutaneous, intratumoral and intraperitoneal routes. It is a recombinant soluble human lymphocyte-activation gene 3 (LAG-3) IgG Fc fusion protein. The drug candidate is developed by using ImmuFact technology.
The drug candidate was also under development for triple-negative breast cancer, pancreatic adenocarcinoma, metastatic renal cell carcinoma, coronavirus disease 2019 and prostate cancer.
Immutep overview
Immutep is a developer of immunotherapeutic products for the treatment of cancer and autoimmune diseases. The company provides products based on the LAG-3 immune control mechanism which is active in the regulation of the T cell immune response. It develops IMP761, a humanized monoclonal antibody that binds to LAG-3 and autoreactive T-cells as an agonist to reduce immune reactions in autoimmune diseases, and others. Immutep’s IMP321 is in clinical development for the treatment of a range of cancer indications. The company partners with pharmaceutical and biotech companies for research and development activities. It has operations across Australia, Germany and France. Immutep is headquartered in Sydney, New South Wales, Australia.
For a complete picture of Eftilagimod alfa’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
